T1 renal cell carcinoma, defined as tumors 7 cm or smaller confined within the kidney, represents the majority of newly diagnosed RCC cases. With multiple effective treatment options available, selecting the optimal approach for each patient requires careful consideration of oncologic outcomes, kidney function preservation, and patient-specific factors.
Robot-assisted partial nephrectomy (RAPN) is the standard surgical approach for eligible T1 RCC patients, offering the ability to remove the tumor while preserving the remainder of the kidney. Robotic assistance improves surgical precision and reduces the learning curve compared to open partial nephrectomy.
Percutaneous cryoablation (PCA) is an alternative minimally invasive option where extreme cold is applied through needles inserted through the skin to destroy the tumor. PCA is particularly attractive for elderly patients or those with significant comorbidities who may not tolerate general anesthesia or surgery.
Comparative data between RAPN and PCA on long-term oncologic outcomes and kidney function are important for clinical decision-making, yet few retrospective series have systematically compared these approaches in the same institutional setting with matched follow-up.
This retrospective study included 126 patients treated for clinical T1 RCC at Osaka University Hospital between 2010 and 2018: 78 underwent RAPN and 48 underwent PCA. All patients had histologically or radiologically confirmed RCC, with tumor size 7 cm or smaller by imaging.
The two treatment groups were compared on baseline clinical characteristics including age, tumor size, tumor complexity (RENAL score), comorbidities, and preoperative kidney function (estimated glomerular filtration rate, eGFR). Differences in baseline characteristics were accounted for in multivariable analyses.
Primary endpoints were overall survival (OS) and recurrence-free survival (RFS) at 3 years, analyzed by Kaplan-Meier survival curves with log-rank tests for between-group comparison. Secondary endpoints included perioperative complications, hospital stay duration, and postoperative eGFR preservation.
eGFR preservation was calculated as the percentage of preoperative kidney function retained at 12 months postoperatively. This metric directly reflects the degree to which each treatment approach maintains the functioning kidney mass.
Three-year overall survival did not differ significantly between RAPN and PCA groups (p = 0.17). Both groups achieved high overall survival rates consistent with the generally favorable prognosis of T1 RCC when treated with curative intent.
Three-year recurrence-free survival also showed no statistically significant difference between the two groups (p = 0.093), though there was a trend toward higher local recurrence in the PCA group consistent with the known limitation of ablative therapies in achieving complete destruction of larger T1b tumors.
Kidney function preservation was comparable between the two approaches, with both RAPN and PCA groups maintaining approximately 91% of preoperative eGFR at 12-month follow-up. This equivalence in functional preservation supports PCA as a viable alternative to surgery for patients with competing kidney disease concerns.
Perioperative morbidity differed between the groups: RAPN was associated with longer operative times and hospital stays, while PCA patients had shorter procedure times and faster recovery. Complication rates were low in both groups, consistent with the minimally invasive nature of both techniques.
The equivalent oncologic outcomes support the use of PCA as a clinically appropriate alternative to RAPN for T1 RCC in carefully selected patients. Age, performance status, anesthesia risk, tumor location, and patient preference are key individualized factors driving the choice.
PCA's advantage in perioperative morbidity (shorter hospital stay, faster recovery, local anesthesia feasibility) makes it particularly suitable for elderly patients or those with significant cardiovascular or pulmonary comorbidities where general anesthesia carries elevated risk.
RAPN may be preferred for younger patients with longer life expectancy where maximizing oncologic control is paramount, for larger T1b tumors where ablation completeness is less certain, and for tumors in locations that are technically challenging for percutaneous needle placement.
The similar eGFR preservation in both groups is reassuring for patients with chronic kidney disease or a solitary kidney, where kidney function retention is as clinically important as oncologic control. Both approaches appear to achieve this goal comparably in T1 disease.
The retrospective, single-institution design limits the generalizability of these findings and introduces inherent selection bias: patients selected for PCA were generally older and had higher comorbidity burdens, which confounds direct comparisons even with multivariable adjustment.
The relatively small sample size (78 RAPN, 48 PCA) limits statistical power to detect modest differences in oncologic outcomes. The p-value of 0.093 for RFS, while not meeting conventional significance thresholds, may reflect a real trend toward higher local recurrence with PCA that would reach significance in a larger study.
Three-year follow-up may be insufficient to capture late recurrences, which can occur years after treatment in RCC. Longer-term surveillance data would strengthen conclusions about oncologic equivalence between the two approaches.
These findings are consistent with several larger retrospective series and meta-analyses from other institutions, suggesting that the Osaka University experience reflects a generalizable pattern rather than an institution-specific result influenced by unusual patient selection or surgical expertise.
This retrospective comparison of RAPN and PCA for T1 RCC at a single Japanese academic center confirms the oncologic equivalence of both approaches for most T1 tumors, supporting current guidelines that list both as standard options.
The comparable kidney function preservation argues against a systematic functional disadvantage of either approach, which had been a concern in earlier comparisons where PCA was assumed to preserve more surrounding parenchyma than surgical excision.
Clinical decision-making should continue to be individualized, integrating tumor-specific factors (size, location, complexity) with patient-specific factors (age, comorbidities, life expectancy, preferences) rather than applying a single approach uniformly.
Future prospective randomized trials or large registry-based studies with extended follow-up beyond 5 years are needed to definitively characterize the long-term oncologic outcomes and the role of each treatment modality in specific patient subgroups within T1 RCC.